michael atkins, md, offers opinion on io-tki combinations in renal cell cancer
Published 5 years ago • 48 plays • Length 1:20
Download video MP4
Download video MP3
Similar videos
-
1:15
michael b. atkins, md, on selecting i-o and tki combinations for the treatment of 1st line rcc
-
0:40
michael atkins, md, considers how to treat mrcc after combination i-o in the 1st line setting
-
0:55
michael atkins, md, on mrcc patients whose cancer returns and were previously treated with i-o
-
0:44
michael atkins, md, on follow up investigation of checkmate 025 in renal cell carcinoma patients
-
1:37
michael b. atkins, md, comments on clinical trials investigating the use of i-o and tkis in rcc
-
1:00:50
deciphering immuno-oncology: targeting innate immunity in cancer
-
9:57
how to select 1st line therapy for metastatic renal cell cancer?
-
8:46
today immunotherapy can cure even fourth stage cancer: dr dattatreyudu nori
-
0:41
michael atkins, md, on appropriate patient types to receive a tki in the treatment of 1st line rcc
-
0:58
michael atkins, md, regarding the keynote 426 phase iii trial in metastatic renal cell carcinoma
-
0:51
michael atkins, md, shares exciting potential of current late-stage clinical studies in rcc patients
-
8:32
dr. michael b. atkins on treating advanced kidney cancer
-
0:38
michael atkins, md, considers intermediate/poor & favorable risk rcc patients
-
1:08
che-kai tsao, md, considers the various i-o and tki combinations available for 1st line rcc
-
1:31
combining immunotherapy with vegf inhibitors to treat kidney cancer
-
0:26
michael atkins, md, regarding single agent tkis in the 1st line setting
-
1:23
dr. atkins on sequencing of immunotherapy combination regimens for rcc
-
7:20
emerging immunotherapy combinations in kidney cancer
-
11:23
new targets, new pathways michael b. atkins, m.d.
-
1:08
michael b. atkins, md, on the role of imdc classification in treatment decision-making
-
2:01
michael atkins, md, discusses checkmate-214 investigating nivolumab ipilimumab in rcc patients
-
0:52
michael b. atkins, md, considers preferred agents in the treatment of rcc in the 2nd line
Clip.africa.com - Privacy-policy